# Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)

> **NCT06332508** · PHASE1 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DEVICE:** Pulsed electromagnetic fields (PEMFs)
- **DEVICE:** Pulsed electromagnetic fields (PEMFs)
- **COMBINATION_PRODUCT:** Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane

## Key facts

- **NCT ID:** NCT06332508
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-30
- **Primary completion:** 2025-08-08
- **Final completion:** 2025-08-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332508, "Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06332508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*